Pluristyx, Inc

Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The companys proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and...

Stem cells,cell therapy,process development,cmc project management,manufacturing,consulting,car t-cells,ipsc,pluripotent stem cells,scale-up,cryopreservation,gene therapy,gene editing,drug development,regenerative medicine,cryopreservation,reprogramming,and gmp banking

Pluristyx, inc operates in the Biotechnology industry.

Pluristyx, inc's revenue is 11m - 100m

Pluristyx, inc has 11 - 50 employees.